Compare Skyworks Solutions Inc (SWKS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Skyworks Solutions Inc trades at $69.8 (market cap $10.28B), while State Street SPDR S&P Biotech ETF trades at $159.21. The key difference: Skyworks Solutions Inc pays a 4.13% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Skyworks Solutions Inc nearer its low. Which is the better fit depends on your goals.
| SWKS | XBI | |
|---|---|---|
Market Cap | $10.28B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $83.40 | $164.28 |
52-Week Low | $52.50 | $86.92 |
Enterprise Value | $10.16B | — |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $69.82, up 1.5% today, with a bullish technical signal and strong recent earnings beats. The company reported Q3 2026 EPS of $1.08, exceeding expectations, driven by broad markets and AI data center growth. However, revenue and net income have trended downward from 2022 peaks. Analyst consensus is a Buy (58.34%), with a $66.00 price target, though the current price exceeds this. The pending Qorvo combination is a key strategic focus.
The outlook is mixed; solid execution and the Qorvo deal offer long-term potential, but near-term revenue contraction, margin pressure, and a recent SEC investigation pose risks. The stock's valuation appears full relative to earnings growth, suggesting cautious optimism is warranted amid integration uncertainties and macroeconomic headwinds affecting the semiconductor sector.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
